ライフサイエンスコーパス: study group

1 nts (116 in the control group and 115 in the study group).

2 center, international cohort (the Global PBC Study Group).

3 rican study groups, and 20 from Asia-Pacific study groups).

4 ol group and 42 females and two males in the study group.

5 tals participating in the Dutch Pancreatitis Study Group.

6 andomly assigned to ThuVARP or TURP, 205 per study group.

7 3-59 months were randomised by household to study group.

8 Loss to follow-up did not differ by study group.

9 r 3 monthly injections of ranibizumab in the study group.

10 ported by The Young Infants Clinical Science Study Group.

11 ata from 24 centres of the International RBD Study Group.

12 posed by the International Widefield Imaging Study Group.

13 glycaemia with ketonaemia occurred in either study group.

14 he main single cause of death (16.3%) in the study group.

15 delivery, with no significant difference by study group.

16 genicity and safety were assessed by blinded study group.

17 Merck, International Breast Cancer Study Group.

18 ) and 30 without CHD (CHD-) of the HIV-HEART study group.

19 t and diet contributed to PR exposure in our study group.

20 Seven male beagle dogs comprised the study group.

21 ereas it was > 4 mm thick in 48 heels in the study group.

22 cm(2) [IQR, 73-204], P=0.36) for the entire study group.

23 to the International Vitreomacular Traction Study Group.

24 CT, CRF, CH, and IOP were compared among the study group.

25 e in incidence of adverse events between the study groups.

26 Mean hospital stay was 48 h in both study groups.

27 nce in change in QoL of 7 points between the study groups.

28 ncy or infant outcomes were observed between study groups.

29 to maintain differences in treatment between study groups.

30 s used to estimate cost differences for both study groups.

31 ound among placental compartments and across study groups.

32 e characteristics were well balanced between study groups.

33 f adverse events was similar between the two study groups.

34 use of different escalation protocols in the study groups.

35 he extent of improvement was similar in both study groups.

36 ants who met eligibility criteria in the two study groups.

37 f women who participated in screening in the study groups.

38 ter treatment with purified albumin from the study groups.

39 nts and low use with steady partners in both study groups.

40 e is significantly different between the two study groups.

41 ion did not significantly differ between the study groups.

42 all other analytes was unchanged between the study groups.

43 whom 1132 patients were randomly assigned to study groups.

44 genes across serum samples between different study groups.

45 t-risk population at different rates between study groups.

46 gher in the combined group than in the other study groups.

47 2,485 individuals were randomized into the 3 study groups.

48 and patients were followed up by individual study groups.

49 ved, income breeding small mammals, an under-studied group.

50 d TCT were analyzed and compared between the studied groups.

51 s well as insulin resistance among the eight studied groups.

52 /DMT and TCT maps in differentiating between studied groups.

53 Study group 1 consumed beer up to a breath alcohol conce

54 (mean age 23.9), 50% female, were included (study group 1 n = 31, study group 2 n = 31, controls n =

55 Study groups 1-3 received ALVAC-HIV+AIDSVAX B/E, AIDSVAX

56 eractive web response system to one of three study groups (1:1:1) testing different regimens of triva

57 bstracts detailed the interventions for both study groups (100%) and 81% (95% CI, 78%-85%) reported t

58 randomized in a 1:1 ratio to PPV plus IVB ([study group] 102 eyes) or PPV plus sham ([control] 112 e

59 randomized International Extranodal Lymphoma Study Group 19 (IELSG-19) trial.

60 female, were included (study group 1 n = 31, study group 2 n = 31, controls n = 28).

61 nd then wine to BrAC >=0.11% (vice versa for study group 2).

62 r cataract surgery was similar between the 2 study groups: 2.4 per mille (95% confidence interval = 1

63 cute lymphocytic leukaemia (77 from European study groups, 25 from North American study groups, and 2

64 (2) reported patients with MCI as a primary study group, (3) reported depression or depressive sympt

65 rt of study treatment was similar in the two study groups: 30 children died in the co-trimoxazole gro

66 Finding alternatives to intensively studied group 4 d(0) and late-transition-metal catalysts

67 up (25-30 W) and the last 50 patients in the study group (40-50 W).

68 In both study groups, 5.0 mg/kg of cyclosporine was administered

69 Out of 1,773 women in the study group, 64 (3.6%), developed preeclampsia.

70 mplexes equivalent to their much more widely studied group 7 analogues.

71 In the study group, a BPA alerted providers of the diagnostic r

72 In the study group, a BPA alerted providers of the diagnostic r

73 Patients were assigned to 1 of 4 study groups: A (no anemia); A, ID, T (no anemia, iron-d

74 Participants in the study group additionally received oral olanzapine 0.14 m

75 es or related metabolites were found between study groups after 26 wk of intervention and no signific

76 re significantly different between the three studied groups (all P < 0.01) except full thickness dens

77 Participants were aware of study group allocation.

78 n viral suppression was not superior between study groups, an a-priori test for non-inferiority was d

79 ncer were 2.0 per 1000 screened women in the study group and 1.5 per 1000 screened women in the contr

80 ns screened, 158 were randomly assigned to a study group and 150 initiated treatment: DOT (n = 51), G

81 24 hours and >300 mg/24 hours, respectively) study group and 18 healthy volunteers.

82 bleeding was noted in 32 (31.3%) eyes in the study group and 58 (51.7 %) eyes in the control group (P

83 ime of 9.5 years, mortality was 24.2% in the study group and 6.3% in the control group (P < 0.001).

84 rgical time was 71.3 +/- 32.1 minutes in the study group and 83.6 +/- 38.7 minutes in the control gro

85 nd point was achieved in 164 patients in the study group and 85 patients in the control group.

86 Interaction analyses controlling for study group and maternal atopy confirmed that maternal p

87 nd a total of 17 patients died (eight in the study group and nine in the control group).

88 ed glomerular filtration rate between the RF study group and PF controls.

89 Members of the International PSC Study Group and radiologists from North America and Euro

90 h a functioning graft (seven of eight in the study group and seven of nine in the control group).

91 adiofrequency applications were stopped 2 s (study group and swine) or 5 s (control group) after unip

92 numbers of patients with the outcome in each study group and synthesised the results with odds ratios

93 The mean OPA in the study group and the control group were 2.01 +/- 0.69 mmH

94 d to compare the OCTA biomarkers between the study group and the control group.

95 Rome criteria were fulfilled by 15.6% of the study group and we found the highest prevalence of const

96 s and high cost, they tend to evaluate small study groups and as a result might not provide comprehen

97 There was a significant interaction between study groups and changes over time for total skill score

98 djusted for age and sex were used to compare study groups and explore associations between MRI and cl

99 s in the phenotypes of organoids between our study groups and found considerable variations in their

100 Children with ALL were allocated to study groups and received a single dose of PCV13: Group

101 Children with ALL were allocated to study groups and received a single dose of PCV13: group

102 ive cancer were 0.5 per 1000 screened women (study group) and 1.3 per 1000 screened women (control gr

103 ast cancer were 3.9 per 1000 screened women (study group) and 5.6 per 1000 screened women (control gr

104 Fifty patients with PCR-positive AK (study group) and 50 patients with bacterial, fungal, vir

105 d intraoperatively in 35 eyes (34.3%) in the study group, and 66 eyes (58.9%) in the control group (P

106 Inflammation Society, International Uveitis Study Group, and Foster Ocular Immunological Society, se

107 uropean study groups, 25 from North American study groups, and 20 from Asia-Pacific study groups).

108 from programme administrators from the COBIN study group; and popualtion and other data from WHO, the

109 nction, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2

110 hin 90 days of LT predicted poor survival in study group as well as control groups.

111 s, trial nurses, and midwives were masked to study group assignment throughout the trial.

112 re-printed scratch cards were used to reveal study group assignment.

113 nnel, and treating physicians were masked to study group assignment.

114 Patients, who were masked to study-group assignment, were asked to rate chest discomf

115 sation program, with minimisation to balance study group assignments according to maternal age (<30 y

116 Graft survival probability of the study group at 12, 24, 36, and 48 months was 75%, 60%, 4

117 TMVR with the valve was feasible in a study group at high or extreme risk for conventional mit

118 ronary revascularization were similar in the study groups at 5 years.

119 05), with no significant differences between study groups at all time-points (P > 0.05).

120 raocular pressure (IOP) was similar for both study groups at month 36 (mean +/- standard deviation 14

121 s, subjects in each aim were stratified into study groups based on their treatment center's character

122 1394 newborns were randomly assigned to study groups between Nov 19, 2014, and Nov 18, 2016; 693

123 ted to the central coordinating center (TIMI Study Group, Boston, MA).

124 complications was not different between the study groups (BSG, n = 3; SG, n = 2; P = 0.63).

125 KSHV seroprevalence did not differ by study group but was associated with age.

126 Patients were masked to the study group, but it was not possible to mask hospital st

127 tidiarrheal medications were required in the study group, but this did not translate into demonstrabl

128 1c), blood pressure, and cholesterol in both study groups, but between-group differences identified a

129 erior in improving positive symptoms in both study groups, but not for negative symptoms.

130 by the International Vitreomacular Traction Study Group by 2 independent masked observers.

131 s with access to the raw data were masked to study group by coding the groups until after the analyse

132 tis patients were randomly assigned to three study groups by a consecutive number in ascending order:

133 ter, prospectively collected data in the CDH Study Group (CDHSG) registry, abstracted between 2015 an

134 s of SIOP Europe International Neuroblastoma Study Group, Children's Oncology Group, and Gesellschaft

135 the SIOP Europe International Neuroblastoma Study Group, Children's Oncology Group, and Gesellschaft

136 otal of 351 patients from the German Hodgkin Study Group clinical trials (HD7, HD8, and HD9) were inc

137 DIAN (Dominant Inherited Alzheimer Network) study group cohort with amyloid positron emission tomogr

138 MACs yield a better characterization of the studied groups compared to results obtained from a class

139 rmy was necessary in 28 (27.4 %) eyes in the study group, compared with 75 (66.9%) eyes in the contro

140 The study group comprised of 33 skeletal Class II malocclusi

141 The U.S. Acute Liver Failure Study Group, comprised of 33 tertiary care liver centers

142 The study group consisted of 1148 girls (47.2%) and 1286 boy

143 The study group consisted of 154 eyes: 36 controls, 64 prepe

144 The study group consisted of 35 cases with RSL and 38 contro

145 The final study group consisted of 453 participants who were rando

146 The study group consisted of 9 patients with peripapillary S

147 The study group consisted of patients with incessant FAT (la

148 The study group consisted of thirty-two eyes (13 female and

149 Each study group contained 60 subjects (30 females and 30 mal

150 CR-POPFs were defined by 2016 International Study Group criteria, and risk models generated using st

151 e of Allergy and Infectious Diseases Mycoses Study Group criteria.

152 e Magnetic Resonance Imaging in MS (MAGNIMS) study group critically review the application of brain a

153 in the Consecutive Cooperative Osteosarcoma Study Group database with primary central high-grade ost

154 ence rates: 79.4% in control versus 78.3% in study group (Delta=1.15%; 90% confidence interval, -10.3

155 shedding, but extensive variation in assays, study group demographics and laboratory protocols across

156 f 2.7 years (IQR, 1.5-4.6 years) in the main study group, diabetes was diagnosed in 58 participants (

157 Study groups did not significantly differ by age, sex, b

158 ding cereal to the bottle, despite observing study group differences in FBs.

159 e at 12 months (90% versus 88%; P=0.75), the study group displayed higher first-pass PVI (92% versus

160 d to clinical severity of stroke between the study groups divided depending on the extent of brain at

161 enrolled in the European Soft Tissue Sarcoma Study Group (E pSSG) RMS 2005 study.

162 inary expert panel of members of the Mycoses Study Group Education and Research Consortium.

163 the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria.

164 The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investigate whether prolong

165 , the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) proposed a conservative treatment al

166 xamined by an ophthalmologist blinded to the study group every 4 days and at the time of withdrawal f

167 However, progression-free survival in both study groups exceeded the original statistical assumptio

168 ng individual patient data from the European Study Group for Pancreatic Cancer (ESPAC)-3 randomized c

169 This differed between metabolite classes and study groups-for example, phospholipids showed maximal d

170 and over the two years of follow-up, in the study group from one to six angio-computed tomographic s

171 In total, study groups from 46 cohort studies in 34 countries-29 (

172 lygenic risk score (PRS) models in three PTC study groups from Ohio (1,544 patients and 1,593 control

173 There were 51 eyes of 49 patients in the study group (GDD = 32 eyes, no GDD = 19 eyes) and 43 eye

174 sis using the database of the German Hodgkin Study Group (GHSG).

175 9 months (cross-sectional analysis) between study groups (group 2 vs group 1, difference in mean sco

176 Compared with controls, the study group had a significantly shorter cryotherapy time

177 Every partaker in the study groups had one dental implant placed in posterior

178 At week 26, study groups had similar adherence to the MedDiet but pa

179 Although both the study groups had similar and significant improvement in

180 Four patients (two in each study group) had skin grafts.

181 All participants, except 1 (99.3%) in each study group, had a rabies antibody titer >0.5 IU/mL on d

182 This study group has previously identified IL-9-producing muc

183 arch and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers wh

184 fter ES-HL treated within the German Hodgkin Study Group HD10+HD13 trials.

185 flow cytometry was not different between the study groups; however, values of the majority of capilla

186 injected in right eyes of 14 rats (low dose; study group I, high dose; study group II).

187 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group.

188 detected in the control positive groups and study group (I).

189 tional Association of Diabetes and Pregnancy Study Groups (IADPSG), with 159 women having a diagnosis

190 14 rats (low dose; study group I, high dose; study group II).

191 tatistically significant differences between study groups in any of the secondary participant end poi

192 gnificant differences were found between the study groups in biofluid cytokine levels at 1 and 3 mont

193 e primary outcome was the difference between study groups in the proportion of isotonic crystalloid a

194 re was no significant difference between the study groups in the proportion of patients achieving cul

195 There was no significant difference between study groups in the rate of change of low-luminance visu

196 uping phenomena, and provide a framework for studying grouping in natural signals.

197 The study group included 13,089 opioid-related deaths partit

198 The study group included 17 patients with COVID-19 (12 men,

199 The study group included all consecutive eyes undergoing pri

200 power as the established Acute Liver Failure Study Group index (C-statistic 0.87 vs. 0.85) and was be

201 al of 432 infants were included across three study groups: infants at high risk who developed ASD (N=

202 In the study group, irrespective of prerevascularization severi

203 arians and vertebrates but lost in all other studied groups, is expressed in the nervous system in th

204 tumour, previous antiangiogenic therapy, and study group language, and were centrally randomly assign

205 nts were categorized into 2 groups: group A (study group): <=15 kg (n = 165) and group B (control gro

206 The study group manifested a lower endothelial cell density

207 I-RADS categorisation by radiologists in the studied group matches the literature data according to a

208 iation]) were evaluated; 34 641 women in the study group (mean age, 59 years +/- 6) were screened wit

209 A total of 26 474 women in the study group (mean age, 60 years +/- 5) and 45 543 women

210 The main study group (n = 389) had first-phase insulin release on

211 baseline or apnea, no wave for 10 seconds) (Study group, n = 55), or when the Observer Assessment of

212 The study group number is inadequate to allow statistical co

213 Galpha(13) subtypes together form the least studied group of heterotrimeric G proteins.

214 Allosteric modulators are an intensively studied group of receptor ligands because of their selec

215 global sample of one of the most intensively studied groups of lichens, the wolf lichens (genus Letha

216 This cross-sectional study comprised a study group of 30 eyes from 30 patients with NAION and a

217 enters for esophageal surgery, we selected a study group of 334 patients (31.6%) that fulfilled crite

218 d 121 live-born singletons after KT (Italian study group of kidney in pregnancy, national coverage ab

219 ,001 patients and 287,550 controls from five study groups of European descent.

220 4 European, North American, and Asia-Pacific study groups of the Ponte di Legno group were included.

221 pychopharmacology (ACNP) conference hosted a Study Group on 4 December 2017, Establishing best practi

222 ing clinically significant PF (International Study Group on Pancreatic Fistula Grade B or C) and hosp

223 B/C POPF according to the 2005 International Study Group on Pancreatic Surgery (ISGPS) definition.

224 The primary outcome was POPF (International Study Group on Pancreatic Surgery grade B/C).

225 h delayed iron had no effect in any of the 3 study groups on the primary study outcomes (hemoglobin c

226 rences in questionnaire return rates between study groups or between women who did and did not have M

227 n registry databases from nine international study groups or treatment centers.

228 way included women screened with DBT and SM (study group) or DM alone (control group) between Februar

229 r respiratory tract symptoms (LRTSs) between study groups over the first 4 days of infection.

230 ne phosphatase levels decreased in the three studied groups (P < 0.05).

231 TBUT was significantly reduced in both the study groups (P = 0.001) without significant reduction r

232 , 24 week relapse events were similar across study groups (p=0.44).

233 did not differ significantly between the two study groups (p=0.98).

234 ll types of LTs were compared according to 4 study groups: patients transplanted between 1998 and 200

235 nfavorable cHL treated in the German Hodgkin Study Group phase 2 NIVAHL trial.

236 The West German Study Group PlanB trial evaluated an anthracycline-free

237 In the West German Study Group PlanB trial, 5-year outcomes for TC and EC-T

238 All subjects in both study groups possessed a rabies antibody titer >0.5 IU/m

239 al performed by the Type 1 Diabetes TrialNet Study Group previously demonstrated that low-dose anti-t

240 .797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766

241 t have resulted in contamination between the study groups, reducing the effect size of the interventi

242 No differences were found between the two study groups regarding age at first IAC injection, disea

243 tive ALF patients from the United States ALF Study Group registry between January 1998 and December 2

244 retrospective cohort study based on the CDH Study Group registry for the period of 2007-2017.

245 study was performed using ECLS-eligible CDH Study Group registry patients born between 2007 and 2019

246 examination of 40 cytokine levels across the study groups revealed that anti-VEGF treated patients wi

247 ch and Treatment of Cancer or German Hodgkin Study Group risk group and EFS, before or after adjustin

248 Across the study group, Rothia, Neisseria, and Haemophilus spp. wer

249 rning the percentage of hexagonal cells, the study group showed a lower hexagonality than the control

250 As our study group spent only a portion of their time in proxim

251 d intervention day (crossover) >=1 wk later, study-group subjects were switched to the opposite drink

252 mation Society and the International Uveitis Study Group, systematically developed evidence- and expe

253 us adverse events was low and similar across study groups (ten [9%] patients in the amiloride group,

254 ee survival were significantly longer in the study group than in the control group (both were 28 mont

255 s from lancelets (lanFPs) is a new and least studied group that already generated several outstanding

256 Thirty-two patients were randomized into two study groups that were not significantly different in de

257 On the basis of the blinded study group, the vaccine regimens were tolerable and no

258 Among the study groups, the 1-, 3-, and 6-month graft survival rat

259 In the study group, there were 32 (37%) and 54 (67%) metastatic

260 cells were detectable in pancreata from all study groups, tissues from individuals >2 years of age c

261 Only 4 studies compared the study group to a control group in which patients were fe

262 The T-PLL International Study group (TPLL-ISG) set out to define standardized cr

263 The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjust

264 partum, and postpartum complications between study groups using hierarchical logistic regression.

265 verse events (11 [1%] of 763 patients in the study group vs four [1%] of 378 patients in the control

266 Endothelial cell loss in the study group was 12%-22% higher than the control group at

267 red to preoperative donor ECD for the entire study group was 33 (+/-16)%, 36 (+/-17)%, and 52 (+/-18)

268 for both Acanthamoeba and fungi (4.5% of the study group was Acanthamoeba and fungal keratitis positi

269 Each study group was compared separately to a contemporary no

270 severe intraventricular hemorrhage events by study group was observed at the first interim analysis;

271 Thrombolysis In Myocardial Infarction (TIMI) Study Group was performed to determine the impact of sex

272 The consensus of the study group was that data does not currently exist to su

273 perative best-corrected visual acuity of the study group was worse than that of another two groups (P

274 ospective cohort study, part of the HEMA-ICU study group, was designed to study the survival of patie

275 ed system of the International Breast Cancer Study Group, was stratified by type of previous endocrin

276 f the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the Lymph2Cx assay for CO

277 Main effects of study group were not significant in judgement bias (F(1,

278 The study groups were comparable with respect to intraoperat

279 keratinized gingival thickness measurements; study groups were divided as thick and thin phenotype.

280 Kinetics of antibody titers over time among study groups were examined.

281 ge at administration of the vaccine) between study groups were included in the analyses, because tria

282 In each aim, the study groups were matched based on propensity score (PS)

283 Both study groups were matched in clinical and laboratory dat

284 When all the study groups were observed together, MT levels were posi

285 ry retinal nerve fiber layer thickness among study groups were statistically significant with lower v

286 Study groups were well matched for baseline demographics

287 (GDD) implantation who later underwent DMEK (study group) were matched for follow-up duration with Fu

288 se 3 trials of the German Low-Grade Lymphoma Study Group, were comparatively analyzed.

289 ea and standard deviation were larger in the study group while the coefficient of variation revealed

290 acute lymphoblastic leukaemia (ALL) in many study groups, whilst outcomes for T-cell ALL are still l

291 of the German Chronic Lymphocytic Leukaemia Study Group who were treated between July 21, 2003, and

292 nce about endothelial cell loss found in the study group with different measurement interval.

293 Only study groups with a BP in the highest 25th percentile of

294 In study groups with mean BP <= 131/78 mm Hg, the relation

295 dose-response relations between SR and BP in study groups with mean BP above or below the 75th percen

296 In study groups with mean BP above the 75th percentile [131

297 comparison of FMD and PISA scores among the study groups with P <0.05.

298 tumor radiation-absorbed dose values in the study groups) with those receiving sorafenib was calcula

299 ost published data have come from east Asian study groups, with little information available from int

300 h stoma)," n = 18 grafts in 16 patients and "Study group (without stoma)," n = 16 grafts in 15 patien